ALKS Alkermes Plc

Price (delayed)

$18.28

Market cap

$2.91B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$3.05B

Sector: Healthcare
Industry: Biotechnology
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Highlights

The EPS has soared by 64% year-on-year and by 43% since the previous quarter
Alkermes's net income has soared by 63% YoY and by 42% from the previous quarter
The debt has grown by 32% YoY
ALKS's quick ratio is down by 8% since the previous quarter and by 2.2% year-on-year

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
159.15M
Market cap
$2.91B
Enterprise value
$3.05B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.68
Price to sales (P/S)
2.48
EV/EBIT
N/A
EV/EBITDA
88.33
EV/Sales
2.61
Earnings
Revenue
$1.17B
EBIT
-$47.46M
EBITDA
$34.58M
Free cash flow
-$11.12M
Per share
EPS
-$0.46
Free cash flow per share
-$0.07
Book value per share
$6.82
Revenue per share
$7.36
TBVPS
$10.45
Balance sheet
Total assets
$1.88B
Total liabilities
$792.46M
Debt
$385.6M
Equity
$1.08B
Working capital
$646.79M
Liquidity
Debt to equity
0.36
Current ratio
2.71
Quick ratio
2.21
Net debt/EBITDA
4.19
Margins
EBITDA margin
3%
Gross margin
84.5%
Net margin
-6.3%
Operating margin
-7.8%
Efficiency
Return on assets
-4%
Return on equity
-6.9%
Return on invested capital
-3.4%
Return on capital employed
-3.2%
Return on sales
-4.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
-1.19%
1 week
0.27%
1 month
12.49%
1 year
-13.04%
YTD
-10.39%
QTD
10.32%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.17B
Gross profit
$989.62M
Operating income
-$91.63M
Net income
-$73.57M
Gross margin
84.5%
Net margin
-6.3%
The net margin has soared by 66% YoY and by 42% from the previous quarter
Alkermes's net income has soared by 63% YoY and by 42% from the previous quarter
The company's operating margin rose by 49% YoY and by 33% QoQ
Alkermes's operating income has increased by 45% YoY and by 32% from the previous quarter

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
P/E
N/A
P/B
2.68
P/S
2.48
EV/EBIT
N/A
EV/EBITDA
88.33
EV/Sales
2.61
The EPS has soared by 64% year-on-year and by 43% since the previous quarter
The P/B is 48% lower than the 5-year quarterly average of 5.2 but 3.1% higher than the last 4 quarters average of 2.6
The company's equity rose by 2.1% QoQ
ALKS's P/S is 66% below its 5-year quarterly average of 7.3 but 3.3% above its last 4 quarters average of 2.4
The revenue has grown by 9% YoY

Efficiency

How efficient is Alkermes business performance
The ROIC has soared by 77% YoY and by 55% from the previous quarter
The ROS has soared by 76% year-on-year and by 53% since the previous quarter
The ROA has soared by 65% YoY and by 43% QoQ
The return on equity has surged by 62% year-on-year and by 42% since the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 137% higher than its total liabilities
The company's total liabilities rose by 15% YoY and by 7% QoQ
ALKS's quick ratio is down by 8% since the previous quarter and by 2.2% year-on-year
The debt is 64% less than the equity
The debt to equity is up by 33% YoY but it is down by 2.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.